Tag: financial report

NEW YORK, June 09, 2026 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that the U.S. Food and Drug Administration (FDA) granted Regenerative Medicine Advanced Therapy (RMAT) designation to lasmecabtagene timgedleucel (lasme-cel), its CD22-targeting allogeneic CAR-T cell therapy product candidate, for the treatment of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (r/r B-ALL).

ProVen VCT plc
Annual Financial Report
Year ended 28 February 2026

European Energy A/S: Q1 2026 report

Om Pharma Equity Group A/S

Consolidated Interim Report 1 January – 30 June 2025
Key points from the H1-2025 report (period 1 January - 30 June 2025)

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In PubMatic (PUBM) To Contact Him Directly To Discuss Their Options

Sp Mortgage Bank Plc  
Stock Exchange Release  
13 August 2025 at 8:00 am (CET +1)  

Wynn Macau is capitalizing on Macau’s strong tourism recovery and robust gaming demand, with Q2 revenue projected to reach $933 million, up 5.5% year-on-year. Enhanced by a surge in VIP baccarat revenue—the highest since 2019—and continued investment in smart gaming technology and diversified non-gaming offerings, Wynn Macau is positioned for further growth. As market sentiment improves and visitor numbers set new records, the company’s strategic upgrades and premium brand are driving renewed investor confidence in the region’s gaming sector.